LYEL

Business Context and Reporting Period

Company: Lyell Immunopharma, Inc. (LYEL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Lyell is a late-stage clinical cell therapy company focused on developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company's lead product candidate, LYL314 (formerly IMPT-314), is a dual-targeting CD19/CD20 CAR T-cell therapy currently in a pivotal Phase 2 trial (PiNACLE) for large B-cell lymphoma. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Note: Per share data reflects a 1-for-20 reverse stock split effected on May 30, 2025.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by $11.6 million for the six months ended June 30, 2025, compared to the same period in 2024. This improvement was driven by a $13.0 million impairment of other investments recorded in 2024 that did not recur in 2025, alongside reduced operating expenses.
• Operating Expenses: Total operating expenses decreased by $2.6 million year-over-year for the six-month period.
  • R&D Expenses: Decreased by $5.1 million, primarily due to reduced costs for research activities, collaborations, and outside services, as well as lower depreciation following the impairment of leasehold improvements.
  • G&A Expenses: Decreased by $1.9 million, driven by lower legal expenses and reduced stock-based compensation, partially offset by severance costs related to the closure of the West Hills manufacturing facility.
• Impairment Charges: The company recognized a $1.4 million impairment of long-lived assets in Q2 2025 related to the right-of-use asset for its West Hills, Los Angeles facility, which was closed following the successful technology transfer to the LyFE Manufacturing Center in Bothell, Washington.
• Interest Income: Net interest income decreased by $6.0 million year-over-year for the six-month period, attributed to lower interest rates and reduced balances of cash equivalents and marketable securities.

Guidance, Outlook, and Risks

• Clinical Progress: The company presented new data from the Phase 1/2 trial of LYL314 at the ICML in June 2025. In the 3L+ setting, the overall response rate was 88% with a 72% complete response rate. In the 2L setting, the overall response rate was 91% with a 64% complete response rate. The pivotal PiNACLE trial is ongoing, with plans to expand trial sites to approximately 35.
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($296.8 million as of June 30, 2025) are sufficient to fund operations for at least the next 12 months. This outlook includes proceeds from a subsequent private placement (see below).
• Subsequent Financing: In July 2025, the company entered into a Securities Purchase Agreement, selling approximately 3.75 million shares for gross proceeds of $50.0 million. The agreement includes a "Milestone Closing" provision allowing the company to require investors to purchase an additional $50.0 million of shares upon the occurrence of a milestone event within 12 months.
• Contingent Consideration: In July 2025, the company issued 625,000 shares of common stock to former ImmPACT stockholders, fulfilling a contingent consideration obligation triggered by a clinical milestone achieved in Q2 2025.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, potential dilution from future financing, manufacturing complexities, and the ability to successfully integrate the ImmPACT acquisition. The company also faces risks related to Nasdaq listing compliance, having recently executed a reverse stock split to regain compliance with the minimum bid price requirement.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $296.8 million cash balance against the burn rate of approximately $89 million per six months, considering the $50 million raised in July 2025.
• Manufacturing Transition: Confirm the operational status and capacity of the LyFE Manufacturing Center in Bothell, WA, following the closure of the Los Angeles facility.
• Clinical Milestones: Monitor enrollment progress in the pivotal PiNACLE trial and the timing of data readouts for the 2L setting, which are critical for the "Milestone Closing" financing provision.
• Dilution Impact: Assess the impact of the 625,000 shares issued for contingent consideration and the potential issuance of up to 3.75 million additional shares under the July 2025 Purchase Agreement.
• Stock Price Volatility: Review the company's compliance with Nasdaq listing requirements post-reverse split and monitor stock price stability.